Recent News

• 08.05.2026 - CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
• 08.05.2026 - Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
• 08.02.2026 - Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
• 07.26.2026 - Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
• 06.14.2026 - Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
• 05.31.2026 - Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
• 05.31.2026 - Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
• 05.31.2026 - Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
• 05.22.2026 - Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
• 05.13.2026 - Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

Recent Filings

• 08.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.05.2026 - EX-99.1 EX-99.1
• 08.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.03.2026 - EX-99.1 EX-99.1
• 07.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.27.2026 - EX-99.1 EX-99.1
• 07.20.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.20.2026 - F-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 07.20.2026 - EX-99.1 EX-99.1
• 07.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]